NCT05193188View on ClinicalTrials.gov

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 6, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2026

Conditions
Chondrosarcoma
Interventions
DRUG

Anlotinib hydrochloride

Anlotinib 12mg per person per day, continuous medication for 2 weeks and 1 week off, 3 weeks 1 cycle, until disease progression or intolerable toxicity

DRUG

PD-1 inhibitor

Intravenous injection, once every 3 weeks, until the disease progression or intolerable toxicity

Trial Locations (1)

Unknown

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER